- Current report filing (8-K)
March 26 2009 - 11:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
________________
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported):
March 25, 2009
AVIGEN, INC.
(Exact name of registrant as specified in charter)
Delaware
|
000-28272
|
13-3647113
|
(State or
Other Jurisdiction of
|
(Commission
File Number)
|
(I.R.S.
Employer Identification
|
Incorporation)
|
|
No.)
|
1301 Harbor Bay Parkway
Alameda,
California 94502
(Address of
principal executive offices and zip code)
Registrants telephone number, including
area code:
(510) 748-7150
______________________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02.
|
|
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
Termination of Named Executive
Officers.
On March 25, 2009, the Board of
Directors (the Board) of Avigen, Inc. terminated the following named executive
officers without cause, effective at the close of business on March 26, 2009:
Kenneth G. Chahine, Ph.D., President and Chief Executive Officer; Michael D.
Coffee, Chief Business Officer; and M. Christina Thompson, Vice President,
General Counsel and Secretary. At the time the Board notified each of Dr.
Chahine, Mr. Coffee and Ms. Thompson of the termination of their respective
employment with Avigen, there was no disagreement between any one of terminated
named executive officers and Avigen.
Appointment of Certain Officers.
On March 25, 2009, the Board appointed
Avigens current Chief Financial Officer, Andrew A. Sauter, 41, to the position
of President and Chief Executive Officer, to be effective upon Dr. Chahines
termination of employment. Mr. Sauter was appointed Chief Financial Officer in
February 2008 after having served as Vice President, Finance since January 2006.
Mr. Sauter joined Avigen as Controller in November 1999. Mr. Sauter is a
certified public accountant and holds a B.A. degree in economics from Claremont
McKenna College.
On March 25, 2009, the Board appointed
Avigens current Vice President, Research and Development, Kirk W. Johnson,
Ph.D., 49, to the position of Corporate Secretary, to be effective upon Ms.
Thompsons termination of employment. Dr. Johnson was appointed Vice President,
Research and Development in December 2006. Dr. Johnson joined Avigen in January
2004 and was appointed Vice President, Preclinical Development in June 2004 and
has played a major role in redirecting the company and establishing the
pipeline. Prior to joining Avigen, Dr. Johnson was Senior Director, Pharmacology
& Preclinical Development and a member of the executive management team of
Genesoft Pharmaceuticals, a pharmaceutical company, from 2001 to 2004. Dr.
Johnson was involved in leading IND-enabling programs, supporting clinical
development, and contributing to successful IND and NDA filings at Genesoft. In
addition to general pharmacology and other preclinical development
responsibilities, he has led research and clinical development projects for
diverse indications including neuropathic pain, hemophilia, antibacterials,
diabetes, obesity, acute inflammation and cardiovascular disease and has
published more than 60 manuscripts and holds 5 U.S. patents. Dr. Johnson earned
a B.S. in toxicology from U.C. Davis, and a Ph.D. in pharmacology and toxicology
from the Medical College of Virginia. He completed postdoctoral fellowships
studying the mechanism of action of IL-2 from 1986-1991 at both Dartmouth
Medical School and the University of California, Berkeley.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 26,
2009
|
AVIGEN, INC.
|
|
|
By:
|
/s/ Andrew
A. Sauter
|
|
|
Andrew A. Sauter
|
|
|
Chief Financial
Officer
|
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Jul 2023 to Jul 2024